JP2001508773A - 徐放性組成物 - Google Patents
徐放性組成物Info
- Publication number
- JP2001508773A JP2001508773A JP53080298A JP53080298A JP2001508773A JP 2001508773 A JP2001508773 A JP 2001508773A JP 53080298 A JP53080298 A JP 53080298A JP 53080298 A JP53080298 A JP 53080298A JP 2001508773 A JP2001508773 A JP 2001508773A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- phase
- diglycerol
- biologically active
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 238000013268 sustained release Methods 0.000 title claims abstract description 12
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 12
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000007788 liquid Substances 0.000 claims abstract description 31
- 239000004973 liquid crystal related substance Substances 0.000 claims abstract description 20
- 229940088623 biologically active substance Drugs 0.000 claims abstract description 18
- 150000002646 long chain fatty acid esters Chemical class 0.000 claims abstract description 3
- 239000012071 phase Substances 0.000 claims description 67
- 239000000194 fatty acid Substances 0.000 claims description 51
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 49
- 229930195729 fatty acid Natural products 0.000 claims description 49
- 150000004665 fatty acids Chemical class 0.000 claims description 34
- -1 diglycerol fatty acid ester Chemical class 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 150000002632 lipids Chemical class 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000005642 Oleic acid Substances 0.000 claims description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 6
- 230000007704 transition Effects 0.000 claims description 6
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 235000021360 Myristic acid Nutrition 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 description 14
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
- 108010036949 Cyclosporine Proteins 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 229960001265 ciclosporin Drugs 0.000 description 9
- 229930105110 Cyclosporin A Natural products 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 229920000223 polyglycerol Polymers 0.000 description 6
- 239000003921 oil Substances 0.000 description 5
- 238000010587 phase diagram Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- MLSVJHOYXJGGTR-IFHOVBQLSA-N acetic acid;(2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,1 Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 MLSVJHOYXJGGTR-IFHOVBQLSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- PHDVPEOLXYBNJY-KTKRTIGZSA-N 2-(2-hydroxyethoxy)ethyl (z)-octadec-9-enoate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCO PHDVPEOLXYBNJY-KTKRTIGZSA-N 0.000 description 2
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 125000005313 fatty acid group Chemical group 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 238000000199 molecular distillation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9700061-6 | 1997-01-13 | ||
| SE9700061A SE511313C2 (sv) | 1997-01-13 | 1997-01-13 | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
| PCT/SE1998/000009 WO1998030206A1 (en) | 1997-01-13 | 1998-01-08 | Controlled release composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001508773A true JP2001508773A (ja) | 2001-07-03 |
| JP2001508773A5 JP2001508773A5 (enExample) | 2005-09-08 |
Family
ID=20405393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53080298A Ceased JP2001508773A (ja) | 1997-01-13 | 1998-01-08 | 徐放性組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6660278B1 (enExample) |
| EP (1) | EP0954287B1 (enExample) |
| JP (1) | JP2001508773A (enExample) |
| AT (1) | ATE243024T1 (enExample) |
| AU (1) | AU5583298A (enExample) |
| CA (1) | CA2277377C (enExample) |
| DE (1) | DE69815659T2 (enExample) |
| SE (1) | SE511313C2 (enExample) |
| WO (1) | WO1998030206A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
| US6887487B2 (en) * | 2001-10-19 | 2005-05-03 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US7439268B2 (en) * | 2003-07-18 | 2008-10-21 | Idexx Laboratories | Compositions containing prodrugs of florfenicol and methods of use |
| US20050049210A1 (en) * | 2003-08-27 | 2005-03-03 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| SG173326A1 (en) * | 2004-06-04 | 2011-08-29 | Camurus Ab | Liquid depot formulations |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2006036983A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Pre-dried drug delivery coating for use with a stent |
| US8124127B2 (en) | 2005-10-15 | 2012-02-28 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| WO2006036964A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Barrier layer |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US20060127437A1 (en) * | 2004-12-13 | 2006-06-15 | Misty Anderson Kennedy | Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids |
| US20070059350A1 (en) * | 2004-12-13 | 2007-03-15 | Kennedy John P | Agents for controlling biological fluids and methods of use thereof |
| US8535709B2 (en) * | 2004-12-13 | 2013-09-17 | Southeastern Medical Technologies, Llc | Agents for controlling biological fluids and methods of use thereof |
| US8288348B2 (en) * | 2005-07-13 | 2012-10-16 | Allergan, Inc. | Cyclosporin compositions |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US8574627B2 (en) | 2006-11-06 | 2013-11-05 | Atrium Medical Corporation | Coated surgical mesh |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| US7550625B2 (en) * | 2007-10-19 | 2009-06-23 | Idexx Laboratories | Esters of florfenicol |
| EP2393472B1 (en) | 2008-12-05 | 2019-06-05 | NanoMed Holdings Pty Ltd | Amphiphile prodrugs |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| WO2011050388A1 (en) * | 2009-10-30 | 2011-05-05 | Monash University | Liquid crystal composition and method of use |
| KR101663551B1 (ko) * | 2010-05-18 | 2016-10-07 | 후지필름 가부시키가이샤 | 카로티노이드 함유 조성물 및 그 제조 방법 |
| WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| LT2877155T (lt) | 2012-07-26 | 2021-02-25 | Camurus Ab | Opioidų vaisto formos |
| PL2877155T3 (pl) | 2012-07-26 | 2021-05-17 | Camurus Ab | Formulacje opioidowe |
| MX391097B (es) | 2017-11-27 | 2025-03-21 | Umecrine Cognition Ab | FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. |
| CN113166189A (zh) | 2018-04-26 | 2021-07-23 | 纳米医学控股有限公司 | 吉西他滨两亲性前体药物 |
| SG11202107877WA (en) | 2018-06-21 | 2021-08-30 | NanoMed Holdings Pty Ltd | Platinum-based amphiphile prodrugs |
| US20240083107A1 (en) * | 2021-01-29 | 2024-03-14 | Ioi Oleo Gmbh | Polyglycerol fatty acid ester-containing composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5321393B2 (enExample) * | 1974-10-19 | 1978-07-03 | ||
| US5264460A (en) * | 1988-05-30 | 1993-11-23 | Deutsche Solvay-Werke Gmbh | Process for preparing nonionic surfactants |
| KR0148748B1 (ko) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| IE65045B1 (en) * | 1990-04-28 | 1995-10-04 | Takeda Chemical Industries Ltd | Granulated preparations and method of producing the same |
| DE69229779T2 (de) | 1991-04-19 | 1999-12-23 | Lds Technologies, Inc. | Konvertierbare mikroemulsionsverbindungen |
| SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| US6013269A (en) * | 1994-10-12 | 2000-01-11 | The Procter & Gamble Company | Cosmetic make-up compositions |
| SE504582C2 (sv) | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyklosporinkomposition baserad på en L2-fas |
| CZ288739B6 (cs) * | 1996-08-01 | 2001-08-15 | Galena, A. S. | Cyklosporin obsahující léčivé přípravky |
-
1997
- 1997-01-13 SE SE9700061A patent/SE511313C2/sv not_active IP Right Cessation
-
1998
- 1998-01-08 CA CA002277377A patent/CA2277377C/en not_active Expired - Fee Related
- 1998-01-08 WO PCT/SE1998/000009 patent/WO1998030206A1/en not_active Ceased
- 1998-01-08 JP JP53080298A patent/JP2001508773A/ja not_active Ceased
- 1998-01-08 AU AU55832/98A patent/AU5583298A/en not_active Abandoned
- 1998-01-08 AT AT98900793T patent/ATE243024T1/de not_active IP Right Cessation
- 1998-01-08 DE DE69815659T patent/DE69815659T2/de not_active Expired - Lifetime
- 1998-01-08 EP EP98900793A patent/EP0954287B1/en not_active Expired - Lifetime
- 1998-01-08 US US09/341,294 patent/US6660278B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU5583298A (en) | 1998-08-03 |
| CA2277377A1 (en) | 1998-07-16 |
| ATE243024T1 (de) | 2003-07-15 |
| EP0954287B1 (en) | 2003-06-18 |
| US6660278B1 (en) | 2003-12-09 |
| EP0954287A1 (en) | 1999-11-10 |
| SE9700061L (sv) | 1998-07-14 |
| CA2277377C (en) | 2007-12-18 |
| DE69815659T2 (de) | 2004-04-29 |
| DE69815659D1 (de) | 2003-07-24 |
| SE9700061D0 (sv) | 1997-01-13 |
| SE511313C2 (sv) | 1999-09-06 |
| WO1998030206A1 (en) | 1998-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001508773A (ja) | 徐放性組成物 | |
| Constantinides | Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects | |
| US7157099B2 (en) | Sustained release pharmaceutical compositions for the parenteral administration of hydrophilic compounds | |
| EP0744939B1 (en) | Bilayer preparations made from digalactosyldiacylglycerol containing galactolipid | |
| KR100220546B1 (ko) | 호지성 담체 제제 | |
| AU763945B2 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
| JP2002513748A (ja) | ゲル化性薬剤組成物 | |
| JP2003526620A (ja) | 長鎖トリグリセリドと親油性界面活性剤とを含有する経口医薬組成物 | |
| JPH10510260A (ja) | 逆ミセル（ｌ２）構造または正常ミセル（ｌ１）構造を形成する制御放出組成物 | |
| AU2001281786A1 (en) | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds | |
| JPH10504532A (ja) | ジアシルグリセロール、リン脂質、極性液体および生物活性物質を含有する脂質をベースとした組成物 | |
| CZ247793A3 (en) | Pharmaceutical preparation containing a defined lipid system | |
| JPH0759523B2 (ja) | 調節放出組成物 | |
| JPH11508592A (ja) | シクロスポリンからなる生物活性組成物 | |
| KR100533460B1 (ko) | 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법 | |
| JP2001501921A (ja) | 免疫調節作用を有する調合物 | |
| EP0302370A1 (en) | Erythromycin formulations for oral administration | |
| EP0521562B1 (en) | Vesicles in non-polar media | |
| CN101137348A (zh) | 大麻素受体结合性化合物的微乳液 | |
| US20040213837A1 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
| CN118526456A (zh) | 一种注射用液晶缓释组合物及其应用 | |
| JP2001513493A (ja) | 経鼻投与用組成物 | |
| GR1010501B (el) | Νανοσυστηματα βιοδραστικων μακρομοριων σε μορφη νανοδομημενων λυοτροπικων υγρων κρυσταλλων | |
| GR1010458B (el) | Νανοσυστηματα βιοδραστικων μακρομοριων με πεπτιδικους δεσμους σε μορφη νανοδομημενων λυοτροπικων υγρων κρυσταλλων | |
| BRPI0720489A2 (pt) | Cápsulas de gelatina compreendendo um ácido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080722 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081022 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081201 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090303 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090526 |